Racial and ethnic minorities are underrepresented in clinical trials of biologics for allergic diseases, but this is not due to a paucity of minorities with allergic diseases. Contrariwise, racial/ethnic minorities bear a disproportionate burden of allergic diseases. To fully reap the benefits of biologic therapies, however, trials should be conducted in representative populations. Advocacy of legislative and regulatory progress by patients, communities, providers, and leading health organizations is necessary. Immediate steps are dependent on self-awareness as stakeholders identify internal disparities and take incremental steps while binding legislative efforts are enacted to ensure lasting change. Read more here.
